SLC38A7 and acute myeloid leukemia: Many studies to date have focused on the metabolic and apoptotic effects of these combinations (e.g., reduced mitochondrial oxidative phosphorylation, lower expression of amino-acid transporters, and increased release of cytochrome c [cyt c] in LSCs), but it is also important to investigate the mechanism by which venetoclax may act synergistically with HMAs to modify epigenetic targets in DNMT3A-mutated AML.